| Document |
Document Title |
|
WO/2019/162873A1 |
Adduct obtainable by interacting: a. a pyrrolic compound of general formula (I) wherein the significance of the substituents is specified in the description and in the claims, and b. an inorganic oxide hydroxide, comprising an oxide and/...
|
|
WO/2019/157856A1 |
The invention discloses a method of preparing a high chiral purity lactam intermediate and brivaracetam. The invention provides a method of preparing a lactam intermediate compound represented by molecular formula D, the method comprisin...
|
|
WO/2019/154343A1 |
The present invention relates to the field of pharmaceutical chemistry, and relates to a capsid protein assembly inhibitor, and in particular, to a compound represented by formula I, a stereoisomer, tautomer, solvate, hydrate, prodrug or...
|
|
WO/2019/154287A1 |
Disclosed are a quaternary ammonium salt compound, a preparation method therefor and a use thereof. Provided is a novel structural compound as shown in formula Ⅰ, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof...
|
|
WO/2019/144484A1 |
The present invention is the first to report a novel crystal form of an S-nitrosocaptopril monohydrate, a preparation method therefor, and an application of the crystal form in the preparation of a pharmaceutical composition for treating...
|
|
WO/2019/142191A1 |
Novel compounds capable of inhibiting methionine metabolic pathway are provided. These compounds are used in inhibiting cystathionin y-synthase (CGS) in general, and in plants, fungi and bacteria, in particular. These compounds of the in...
|
|
WO/2019/006074A9 |
Disclosed are P2X7 receptor ligands having the formula (I) in which R = -(CH2)n-(O-CH2CH2)m-Ol-(CH2)p-X, l= 0-1, m = 0-6, n = 2-3, p = 0-2, and X = Br, CI, F or 18F. In illustrative embodiments, R = -(CH2)n, and n = 2-3. The receptor lig...
|
|
WO/2019/135189A1 |
The present invention provides an improved process for preparation of the L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) or a salt thereof, which is known as Droxidopa; comprising (a) recovery of the by-product compound (V) (as descri...
|
|
WO/2019/131580A1 |
[Problem] To provide a cationic lipid usable for delivering a nucleic acid to cytoplasm. [Solution] The cationic lipid of the present invention is, for example, a compound represented by formula (1) or a pharmacologically acceptable salt...
|
|
WO/2019/128175A1 |
Disclosed are a cocrystal of tocopherol and proline and a preparation method therefor. The cocrystal is in crystalline or partially crystalline form in the environment of normal pressure and room temperature. Compared to the existing toc...
|
|
WO/2019/131695A1 |
The present invention relates to methods for producing 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde by formylation and deprotection and producing 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-y
l]-N-methylmethanamine mono...
|
|
WO/2019/132739A1 |
The present invention relates to the field of organic chemistry and pharmacology and describes novel asymmetric derivatives of polyphenols of the dinaphthalene series of general Formula (I) or general Formula (II), a process of preparing...
|
|
WO/2019/132144A1 |
The present invention relates to a method for purifying an N-substituted maleimide. Specifically, the present invention introduces, after removing an organic solvent from an N-substituted maleimide generation solution, an evaporation app...
|
|
WO/2019/124674A1 |
The present invention relates to an N-substituted maleimide purification method. More particularly, the present invention relates to an N-substituted maleimide purification method wherein advantage is made of the solubility of organic im...
|
|
WO/2019/120256A1 |
The present invention discloses a five-membered heteroaryl ring derivative (I), and an isomer, a solvate, a crystalline form of the solvate, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt thereof. The five-...
|
|
WO/2019/120257A1 |
The present invention relates to an amorphous pyrrolidine derivative as a PPAR agonist and a preparation method thereof.
|
|
WO/2019/121509A1 |
The invention relates to a process for the manufacture of the crystalline compound according to formula (I) comprising the steps (a) deacetylating the final intermediate (FT), (b) forming the crystalline compound according to formula (I)...
|
|
WO/2019/126730A1 |
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are d...
|
|
WO/2019/124345A1 |
The present invention addresses the problem of providing: a polymerizable liquid crystal composition that satisfies the demand for the high-speed response, low-voltage drive, high contrast, long-term reliability, and the like that have h...
|
|
WO/2019/118961A1 |
Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.
|
|
WO/2019/114770A1 |
Disclosed by the present invention are a compound represented by formula (I) and an anti-tumor application thereof. The compound represented by formula (I) has a degrading and inhibiting effect on an anaplastic lymphoma kinase (ALK)-targ...
|
|
WO/2019/115405A1 |
Novel pyrrole derivatives of Formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Acetyl- CoA carboxylase (ACC).
|
|
WO/2019/115586A1 |
The present invention relates to novel compounds which act as modulators of indoleamine 2,3-dioxygenase (IDOl) and to the use of said compounds in the prophylaxis and/or treatment of diseases or conditions mediated by indoleamine 2,3-dio...
|
|
WO/2019/118932A1 |
Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
|
|
WO/2019/116260A1 |
A perfluorinated 1-alkoxypropene represented by general Formula (I), compositions that include such compounds, and methods and systems that include such compositions are provided, wherein Formula (I) is represented by: RfO-CF=CFCF3 where...
|
|
WO/2019/110774A1 |
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: a basal insulin having an isoelectric point (pI) of between 5.8 and 8.5; b) and a co-polyami...
|
|
WO/2019/113079A1 |
Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions a...
|
|
WO/2019/111225A1 |
Compounds and compositions are provided having the structure of Formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein T, T', U, U', V, W, R1, R2, R3', n, o, o', o'', and o''' are as defined herein....
|
|
WO/2019/109415A1 |
The present invention provides a compound that is a compound represented by formula I or its stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug: X-Y-Z Formu...
|
|
WO/2019/109188A1 |
The present application is directed to compounds of Formula (I)-(VI): (I), (II), (III), (IV), (V) (VI), (VII) and (VIII), compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.
|
|
WO/2019/111980A1 |
The present invention provides a compound having an exceptional inhibitory action on EP300 and/or CREBBP histone acetyl transferase, or a pharmaceutically acceptable salt thereof. A compound represented by formula (1) or a pharmaceutical...
|
|
WO/2019/110797A1 |
The invention relates to a composition in the form of an injectable aqueous solution having a pH of between 6.0 and 8.0 and comprising at least: • a) amylin, an amylin receptor agonist or an amylin analog; • b) a co-polyamino acid be...
|
|
WO/2019/108800A1 |
The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.
|
|
WO/2019/107310A1 |
A pyrrole compound represented by formula (1).
|
|
WO/2019/101568A1 |
The invention relates to a method for producing compounds of formula (I), in the case of which compounds in a first step γ-butyrolactone is reacted with diamines of formula (II) to form bisamides of formula (III), the amide function of ...
|
|
WO/2019/104199A1 |
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through ...
|
|
WO/2019/104201A1 |
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through ...
|
|
WO/2019/094732A1 |
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating diseases associated with the binding of CREB to CREB-binding protein (CBP) and...
|
|
WO/2019/089729A1 |
Provided herein are compounds of the general Formula (I) which act as kinase inhibitors, e.g. ROCK, S6K, and/or PKC inhibitors, and are useful in neurite growth and axonal growth.
|
|
WO/2019/087172A1 |
The present invention relates to a process for the preparation of brivaracetam and salts thereof. The present invention provides process for the preparation of brivaracetam and salts thereof with high chiral purity. The present invention...
|
|
WO/2019/090081A1 |
Provided herein are compounds of Formula (I) or Formula (II), compositions, and methods there of useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
|
|
WO/2019/090085A1 |
Provided herein are compounds of formula (I), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. (Formula I).
|
|
WO/2019/090088A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/090090A1 |
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/084030A1 |
The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which bind...
|
|
WO/2019/080226A1 |
The present invention belongs to the technical field of pesticides, and involves more specifically a substituted benzonitril diketone compound or a tautomer, a salt thereof, a preparation method therefor, a herbicide, and an application ...
|
|
WO/2019/079327A1 |
Disclosed herein are methods of methods of treating pain in a subject, reducing opioid dose without increasing pain to a subject, and decreasing pain in a subject without decreasing an opioid dose.
|
|
WO/2019/071162A2 |
The invention relates to a novel process for preparing a-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxami
de, and to novel intermediates for use in said process along wi...
|
|
WO/2019/068841A1 |
The present invention relates to novel compounds of general formula (I) wherein R1 to R4 and n have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or amel...
|
|
WO/2019/070709A1 |
The present invention provides compounds, compositions and methods for treating and/or preventing a flavivirus infection by administering such compounds and compositions.
|
